Mortality rates for Lennox Gastaut syndrome and Dravet syndrome, both developmental epileptic encephalopathies, were ...

Globally recognized pediatric epileptologist and clinical researcher brings deep expertise in Dravet syndrome and genetic medicine –SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...

A sweeping review of more than 2,500 studies reveals that despite booming public enthusiasm, cannabis has strong scientific ...

Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.

Rory Thorner has been a patient at Bristol Children’s Hospital since he was seven months old.

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...

Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) ...

For half a century, the University of Utah's Anticonvulsant Drug Development (ADD) Program has been at the forefront of discovery, helping millions of ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

A review of 2,500+ studies finds medical cannabis has proven benefits for only a few conditions, while many popular claims ...